Phase 2 Trial Shows Antitumor Activity in Metastatic Clear Cell RCC
Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinomaПодробнее
DART Study: Phase 2 study of dalantercept plus axitinib in advanced clear cell RCCПодробнее
NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCCПодробнее
Dr. Motzer on a Phase II Trial of Nivolumab for mRCCПодробнее
Immunotherapy in Renal Cell CarcinomaПодробнее
Managing Advanced Renal Cell Carcinoma - QuinnПодробнее
Len + pembro metastatic clear cell renal cell carcinomaПодробнее
Immunotherapy: Yervoy and BeyondПодробнее
Updates on the CABOPRE Phase II trial in patients with metastatic renal cell carcinomaПодробнее
What is the best front line treatment for metastatic clear cell RCC in 2018?Подробнее
Immunotherapy-based management of metastatic clear-cell and variant RCC: What can we achieve?Подробнее
Metastatic Renal Cell CarcinomaПодробнее
Dr. Hutson Gives an Analysis of the Phase III ATLAS Trial in RCCПодробнее
Neoadjuvant cabozantinib in patients with locally advanced non-metastatic ccRCCПодробнее
RCC MasterClass and Clinical Consult: Novel Immune and Targeted TherapiesПодробнее
Phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinomaПодробнее
Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее
Lenvatinib/Everolimus in Refractory mRCCПодробнее
BIONIKK: the first trial study in mccRCCПодробнее
Immunotherapy for metastatic RCC - EMPIRE Urology Lecture SeriesПодробнее
